{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:51:41Z","timestamp":1770475901429,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1991,1,1]],"date-time":"1991-01-01T00:00:00Z","timestamp":662688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1991]]},"DOI":"10.1007\/bf00684957","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T06:32:53Z","timestamp":1101709973000},"page":"55-58","source":"Crossref","is-referenced-by-count":13,"title":["Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology"],"prefix":"10.1007","volume":"28","author":[{"given":"Simon G.","family":"Allan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Nicolson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moira E.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Soukop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0277-5379(88)90283-0","volume":"24","author":"J Cummings","year":"1988","unstructured":"Cummings J, Smyth JF (1988) Pharmacology of Adriamycin: the message to the clinician. Eur J Cancer Clin Oncol 24: 579?582","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1016\/0006-2952(85)90724-5","volume":"34","author":"DW Fry","year":"1985","unstructured":"Fry DW, Bovityki TJ, Besserer JA, Jackson RC (1985) In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukaemia cells by a new class of DNA complexes ? anthrapyrazoles. Biochem Pharmacol 34: 3499?3508","journal-title":"Biochem Pharmacol"},{"key":"CR3","first-page":"194","volume":"54","author":"MA Graham","year":"1986","unstructured":"Graham MA, Newell DR, Calvert AH (1986) Pharmacological studies with the anthrapyrazole CI941: a new DNA complexing drug. Br J Cancer 54: 194?195","journal-title":"Br J Cancer"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/0006-2952(87)90309-1","volume":"36","author":"MA Graham","year":"1987","unstructured":"Graham MA, Newell DR, Butler J, Hoey B, Patterson LH (1987) The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Biochem Pharmacol 36: 3345?3351","journal-title":"Biochem Pharmacol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-4347(00)82841-8","volume":"491","author":"MA Graham","year":"1989","unstructured":"Graham MA, Newell DR, Calvert AD (1989) Determination of the anthrapyrazole anti-cancer drug CI-941 in plasma and urine by solid phase extraction and high-performance liquid chromatography. J Chromatogr 491: 253?261","journal-title":"J Chromatogr"},{"key":"CR6","first-page":"5532","volume":"45","author":"WR Leopold","year":"1985","unstructured":"Leopold WR, Nelson JM, Plowman J, Jackson RC (1985) Anthrapyrazoles ? a new class of intercalating agents with high level, broad spectrum activity against murine tumours. Cancer Res 45: 5532?5539","journal-title":"Cancer Res"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1126\/science.877547","volume":"197","author":"CE Myers","year":"1977","unstructured":"Myers CE, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumour response. Science 197: 165?167","journal-title":"Science"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","volume":"105","author":"TD Shekenberg","year":"1986","unstructured":"Shekenberg TD, Van Hoff DD (1986) Mitozantrone ? an anti-cancer drug with significant clinical activity. Ann Intern Med 105: 67?81","journal-title":"Ann Intern Med"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/jm00369a002","volume":"27","author":"HD Showalter","year":"1984","unstructured":"Showalter HD, Johnston JL, Werbel LM, Leopold WR, Jackson RC, Elslager EF (1984) 5[(Aminoalkyl)amino]-substituted anthra[1,9-cd] pyrazol-6(2H)-ones as novel anticancer agents. J Med Chem 27: 253?255","journal-title":"J Med Chem"},{"key":"CR10","first-page":"73","volume":"1","author":"HDM Showalter","year":"1986","unstructured":"Showalter HDM, Fry DW, Zeopold WR, Low JW, Plambeck JA, Reszke K (1986) Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles. Anti-cancer Drug Des 1: 73?85","journal-title":"Anti-cancer Drug Des"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Hoff Von","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa F (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710?717","journal-title":"Ann Intern Med"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5","volume":"40","author":"AJ Weiss","year":"1977","unstructured":"Weiss AJ, Manthel RW (1977) Experience with the use of Adriamycin in combination with other anti-cancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 40: 2046?2052","journal-title":"Cancer"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM198107163050305","volume":"305","author":"RC Young","year":"1981","unstructured":"Young RC, Ozols RF, Myers CE (1981) The anthracycline anti-neoplastic drugs. N Engl J Med 305: 139?146","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00684957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00684957\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00684957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:10:08Z","timestamp":1554459008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00684957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1991]]}},"alternative-id":["BF00684957"],"URL":"https:\/\/doi.org\/10.1007\/bf00684957","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991]]}}}